StreetInsider.com News Articles

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Form D Sernova Biotherapeutics

Thu, 05 Feb 2026 15:31:00 -0400

si-local-file:///var/storage/secattach/20260205/25954378.html

Form D Sernova Biotherapeutics

Thu, 05 Feb 2026 15:31:00 -0400

si-local-file:///var/storage/secattach/20260205/25954378.html

Form D Sernova Biotherapeutics

Thu, 05 Feb 2026 15:31:00 -0400

si-local-file:///var/storage/secattach/20260205/25954378.html

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Tue, 16 Dec 2025 12:00:00 -0400

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs[1]. Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year[2]. As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution: Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Tue, 16 Dec 2025 12:00:00 -0400

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs[1]. Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year[2]. As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution: Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Tue, 16 Dec 2025 12:00:00 -0400

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs[1]. Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year[2]. As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution: Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Tue, 16 Dec 2025 12:00:00 -0400

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs[1]. Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year[2]. As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution: Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals